575 related articles for article (PubMed ID: 28880093)
1. Quantification of Transporter and Receptor Proteins in Dog Brain Capillaries and Choroid Plexus: Relevance for the Distribution in Brain and CSF of Selected BCRP and P-gp Substrates.
Braun C; Sakamoto A; Fuchs H; Ishiguro N; Suzuki S; Cui Y; Klinder K; Watanabe M; Terasaki T; Sauer A
Mol Pharm; 2017 Oct; 14(10):3436-3447. PubMed ID: 28880093
[TBL] [Abstract][Full Text] [Related]
2. Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate.
Kodaira H; Kusuhara H; Fujita T; Ushiki J; Fuse E; Sugiyama Y
J Pharmacol Exp Ther; 2011 Dec; 339(3):935-44. PubMed ID: 21934030
[TBL] [Abstract][Full Text] [Related]
3. Quantitative investigation of the brain-to-cerebrospinal fluid unbound drug concentration ratio under steady-state conditions in rats using a pharmacokinetic model and scaling factors for active efflux transporters.
Kodaira H; Kusuhara H; Fuse E; Ushiki J; Sugiyama Y
Drug Metab Dispos; 2014 Jun; 42(6):983-9. PubMed ID: 24644297
[TBL] [Abstract][Full Text] [Related]
4. Blood-brain barrier (BBB) pharmacoproteomics: reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain in mice.
Uchida Y; Ohtsuki S; Kamiie J; Terasaki T
J Pharmacol Exp Ther; 2011 Nov; 339(2):579-88. PubMed ID: 21828264
[TBL] [Abstract][Full Text] [Related]
5. Species difference in brain penetration of P-gp and BCRP substrates among monkey, dog and mouse.
Kido Y; Nanchi I; Fusamae Y; Matsuzaki T; Akazawa T; Sawada H; Iwasaki M; Nishida K; Tsuchiya E; Okuda T
Drug Metab Pharmacokinet; 2022 Feb; 42():100426. PubMed ID: 34974334
[TBL] [Abstract][Full Text] [Related]
6. Brain penetration of WEB 2086 (Apafant) and dantrolene in Mdr1a (P-glycoprotein) and Bcrp knockout rats.
Fuchs H; Kishimoto W; Gansser D; Tanswell P; Ishiguro N
Drug Metab Dispos; 2014 Oct; 42(10):1761-5. PubMed ID: 25053619
[TBL] [Abstract][Full Text] [Related]
7. P-glycoprotein and breast cancer resistance protein expression and function at the blood-brain barrier and blood-cerebrospinal fluid barrier (choroid plexus) in streptozotocin-induced diabetes in rats.
Reichel V; Burghard S; John I; Huber O
Brain Res; 2011 Jan; 1370():238-45. PubMed ID: 21075088
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid can be used as a surrogate to assess brain exposures of breast cancer resistance protein and P-glycoprotein substrates.
Xiao G; Black C; Hetu G; Sands E; Wang J; Caputo R; Rohde E; Gan LS
Drug Metab Dispos; 2012 Apr; 40(4):779-87. PubMed ID: 22266779
[TBL] [Abstract][Full Text] [Related]
9. Inner Blood-Retinal Barrier Dominantly Expresses Breast Cancer Resistance Protein: Comparative Quantitative Targeted Absolute Proteomics Study of CNS Barriers in Pig.
Zhang Z; Uchida Y; Hirano S; Ando D; Kubo Y; Auriola S; Akanuma SI; Hosoya KI; Urtti A; Terasaki T; Tachikawa M
Mol Pharm; 2017 Nov; 14(11):3729-3738. PubMed ID: 28954515
[TBL] [Abstract][Full Text] [Related]
10. Functional Evaluation of P-gp and Bcrp at the Murine Blood-Cerebrospinal Fluid Barrier.
Sun A; Wang J
Pharm Res; 2023 Nov; 40(11):2667-2675. PubMed ID: 37704894
[TBL] [Abstract][Full Text] [Related]
11. Investigation of the role and quantitative impact of breast cancer resistance protein on drug distribution into brain and CSF in rats.
Katagiri Y; Kawaguchi H; Umemura K; Tadano J; Miyawaki I; Takano M
Drug Metab Pharmacokinet; 2022 Feb; 42():100430. PubMed ID: 34896751
[TBL] [Abstract][Full Text] [Related]
12. Elucidation of the Impact of P-glycoprotein and Breast Cancer Resistance Protein on the Brain Distribution of Catechol-
Bicker J; Fortuna A; Alves G; Soares-da-Silva P; Falcão A
Drug Metab Dispos; 2017 Dec; 45(12):1282-1291. PubMed ID: 28916530
[TBL] [Abstract][Full Text] [Related]
13. Characterization and Validation of Canine P-Glycoprotein-Deficient MDCK II Cell Lines for Efflux Substrate Screening.
Ye D; Harder A; Fang Z; Weinheimer M; Laplanche L; Mezler M
Pharm Res; 2020 Sep; 37(10):194. PubMed ID: 32918191
[TBL] [Abstract][Full Text] [Related]
14. Drug Clearance from Cerebrospinal Fluid Mediated by Organic Anion Transporters 1 (Slc22a6) and 3 (Slc22a8) at Arachnoid Membrane of Rats.
Zhang Z; Tachikawa M; Uchida Y; Terasaki T
Mol Pharm; 2018 Mar; 15(3):911-922. PubMed ID: 29436232
[TBL] [Abstract][Full Text] [Related]
15. In vitro assessment of the interactions of dopamine β-hydroxylase inhibitors with human P-glycoprotein and Breast Cancer Resistance Protein.
Bicker J; Alves G; Fortuna A; Soares-da-Silva P; Falcão A
Eur J Pharm Sci; 2018 May; 117():35-40. PubMed ID: 29428540
[TBL] [Abstract][Full Text] [Related]
16. Prediction of Human Brain Penetration of P-glycoprotein and Breast Cancer Resistance Protein Substrates Using In Vitro Transporter Studies and Animal Models.
Feng B; Doran AC; Di L; West MA; Osgood SM; Mancuso JY; Shaffer CL; Tremaine L; Liras J
J Pharm Sci; 2018 Aug; 107(8):2225-2235. PubMed ID: 29608887
[TBL] [Abstract][Full Text] [Related]
17. Susceptibility of juvenile and adult blood-brain barrier to endothelin-1: regulation of P-glycoprotein and breast cancer resistance protein expression and transport activity.
Harati R; Villégier AS; Banks WA; Mabondzo A
J Neuroinflammation; 2012 Dec; 9():273. PubMed ID: 23253775
[TBL] [Abstract][Full Text] [Related]
18. Use of cassette dosing approach to examine the effects of P-glycoprotein on the brain and cerebrospinal fluid concentrations in wild-type and P-glycoprotein knockout rats.
Liu X; Cheong J; Ding X; Deshmukh G
Drug Metab Dispos; 2014 Apr; 42(4):482-91. PubMed ID: 24398459
[TBL] [Abstract][Full Text] [Related]
19. Impact of P-Glycoprotein-Mediated Active Efflux on Drug Distribution into Lumbar Cerebrospinal Fluid in Nonhuman Primates.
Nagaya Y; Katayama K; Kusuhara H; Nozaki Y
Drug Metab Dispos; 2020 Nov; 48(11):1183-1190. PubMed ID: 32862147
[TBL] [Abstract][Full Text] [Related]
20. Estimation of Fetal-to-Maternal Unbound Steady-State Plasma Concentration Ratio of P-Glycoprotein and/or Breast Cancer Resistance Protein Substrate Drugs Using a Maternal-Fetal Physiologically Based Pharmacokinetic Model.
Peng J; Ladumor MK; Unadkat JD
Drug Metab Dispos; 2022 May; 50(5):613-623. PubMed ID: 35149540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
